骨髓增生异常综合征的预后评估随着时间的推移而显著演变，这既归功于诊断分类的演变，也归功于对其预后预测的改善。随着时间的推移，许多预后评分考虑到血液细胞减少的数量和程度，以及骨髓爆发细胞、细胞遗传学特征，以及最近发现的分子突变。所有这些变量从 2022 年起被整合到了 IPSS-M 评分中，一旦患者的分子信息可获得，此评分将迅速成为骨髓增生异常综合征预后评估的参考。版权所有 © 2023 Société Française du Cancer. Elsevier Masson SAS 发布。保留所有权利。

The prognostic evaluation of myelodysplastic syndromes has evolved considerably over time, both due to the evolution of diagnostic classifications and the improvement in the prediction of the outcome. Many prognostic scores that have been developed over time take into account number and depth of blood cytopenias, as well bone marrow blast, cytogenetic, and more recently, molecular mutations. All these variables have been grouped together in IPSS-M score since 2022, which should quickly become a reference for the prognostic evaluation of MDS, as soon as molecular information is available for the patient.Copyright © 2023 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.